Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIgAN: Personalized Therapy in IgA Nephropathy
NCT04662723Phase 4Recruiting
- Sponsor
- Fondazione Schena
- Start
- May 2023
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin, methylprednisolone and prednisolone in immunoglobulin A nephropathy (IgAN) (4 arms), sponsored by Fondazione Schena. Primary endpoint: Proteinuria reduction within 6 months. Started May 2023; status: recruiting.
02
Drugs
dapagliflozinmethylprednisoloneprednisolone
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04662723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662723.